Daniel L. Clemens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel L. Clemens has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Marcus A. Horwitz
University of California – Los Angeles
8 shared publications Bai-Yu Lee
Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA
5 shared publications- Bai-Yu Lee
Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles , Los Angeles, California
3 shared publications - Z. Hong Zhou
Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095, USA
3 shared publications Barbara Jane Dillon
Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California, United States of America
2 shared publications- Jeffrey I. Zink
Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095-1569, USA
2 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (11)
Secretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways
Francisella pathogenicity determinant protein E (PdpE) is a protein of unknown function encoded within the Type VI secretion system (T6SS) gene cluster of the Francisella pathogenicity island, a region essential for bacterial intracellular replication and virulence. We previously showed that PdpE is secreted by the bacteria via a T6SS-independent pathway, but the specific pathway involved was unclear. In this study, we investigated PdpE secretion in Francisella novicida and demonstrated that it requires components of both the Sec general secretory pathway and the Type IV pilus (T4P) secretion system. F. novicida possesses two SecB paralogs, and either of the two paralogs is sufficient for bacterial viability and for T4P-mediated secretion of chitinase and PepO enzymatic activities. In contrast, we found that both paralogs are required for T4P-mediated secretion of PdpE. Bacterial two-hybrid and pulldown assays confirmed interactions between these two SecB chaperones. Genomic analyses indicate that the presence of two secB paralogs is a conserved feature across the family Francisellaceae , including species that lack pdpE , suggesting that—while they have overlapping and partially redundant functions—the two paralogs have evolved to fulfill additional specialized chaperone and/or regulatory functions. IMPORTANCE: Our research shows that pathogenicity determinant protein E (PdpE) secretion in Francisella requires components of both the Sec general secretory pathway and the Type IV pilus (T4P) secretion system, making it the first gene product encoded within a Type VI secretion system gene cluster known to use an alternative pathway. Although genetically linked to PdpC, PdpE’s reliance on an alternative secretion pathway may offer insight into its physiological role. Furthermore, we show that dual SecB chaperone paralogs are required for T4P-mediated PdpE secretion by Francisella , and bioassays indicate a direct interaction between the two distinct chaperones. Genomic analysis reveals that possession of two secB paralogs is a conserved trait within the Francisellaceae family.
- 19 November 2026
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 208 (11)
Open AccessSecretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways
Francisella pathogenicity determinant protein E (PdpE) is a protein of unknown function encoded within the Type VI secretion system (T6SS) gene cluster of the Francisella pathogenicity island, a region essential for bacterial intracellular replication and virulence. We previously showed that PdpE is secreted by the bacteria via a T6SS-independent pathway, but the specific pathway involved was unclear. In this study, we investigated PdpE secretion in Francisella novicida and demonstrated that it requires components of both the Sec general secretory pathway and the Type IV pilus (T4P) secretion system. F. novicida possesses two SecB paralogs, and either of the two paralogs is sufficient for bacterial viability and for T4P-mediated secretion of chitinase and PepO enzymatic activities. In contrast, we found that both paralogs are required for T4P-mediated secretion of PdpE. Bacterial two-hybrid and pulldown assays confirmed interactions between these two SecB chaperones. Genomic analyses indicate that the presence of two secB paralogs is a conserved feature across the family Francisellaceae , including species that lack pdpE , suggesting that—while they have overlapping and partially redundant functions—the two paralogs have evolved to fulfill additional specialized chaperone and/or regulatory functions. IMPORTANCE: Our research shows that pathogenicity determinant protein E (PdpE) secretion in Francisella requires components of both the Sec general secretory pathway and the Type IV pilus (T4P) secretion system, making it the first gene product encoded within a Type VI secretion system gene cluster known to use an alternative pathway. Although genetically linked to PdpC, PdpE’s reliance on an alternative secretion pathway may offer insight into its physiological role. Furthermore, we show that dual SecB chaperone paralogs are required for T4P-mediated PdpE secretion by Francisella , and bioassays indicate a direct interaction between the two distinct chaperones. Genomic analysis reveals that possession of two secB paralogs is a conserved trait within the Francisellaceae family.
- Open Access
- 25 June 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Structure and potential role of T6SS effector PdpC in Francisella tularensis intracellular lifestyle
Francisella tularensis , a gram-negative facultative intracellular pathogen, causes the often-fatal disease tularemia. Its Francisella pathogenicity island (FPI) encodes a type VI secretion system (T6SS) critical for virulence, yet the mechanisms by which T6SS effectors enable intracellular replication remain poorly understood. Here, we report the structure of the T6SS effector PdpC, revealing a novel protein fold with no identifiable homologs. The structure resembles a seahorse, comprising five domains: an N-terminal domain, a central body domain (CBD), a wedge domain, a C-terminal tail, and an unmodeled “mouth” domain. Biochemical analyses demonstrate that PdpC binds host phospholipids, particularly phosphatidylinositol-3-phosphate, and interacts with PdpE, another FPI-encoded protein. Structure-guided functional studies show that the CBD alone suffices for these interactions, while PdpE is secreted via a T6SS-independent pathway. These findings explain how the sophisticated effector duo enables phagosomal escape and establishes infection: PdpC is delivered by T6SS to PI(3)P-enriched early phagosomal membranes to rupture phagosomes to escape, and then coordinates with PdpE to promote intracytoplasmic Francisella replication. This work transforms PdpC from an orphan virulence factor into a tractable molecular switch at the heart of Francisella ’s intracellular lifestyle and a potential target for anti-tularemia therapeutics.
- 25 June 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessStructure and potential role of T6SS effector PdpC in Francisella tularensis intracellular lifestyle
Francisella tularensis , a gram-negative facultative intracellular pathogen, causes the often-fatal disease tularemia. Its Francisella pathogenicity island (FPI) encodes a type VI secretion system (T6SS) critical for virulence, yet the mechanisms by which T6SS effectors enable intracellular replication remain poorly understood. Here, we report the structure of the T6SS effector PdpC, revealing a novel protein fold with no identifiable homologs. The structure resembles a seahorse, comprising five domains: an N-terminal domain, a central body domain (CBD), a wedge domain, a C-terminal tail, and an unmodeled “mouth” domain. Biochemical analyses demonstrate that PdpC binds host phospholipids, particularly phosphatidylinositol-3-phosphate, and interacts with PdpE, another FPI-encoded protein. Structure-guided functional studies show that the CBD alone suffices for these interactions, while PdpE is secreted via a T6SS-independent pathway. These findings explain how the sophisticated effector duo enables phagosomal escape and establishes infection: PdpC is delivered by T6SS to PI(3)P-enriched early phagosomal membranes to rupture phagosomes to escape, and then coordinates with PdpE to promote intracytoplasmic Francisella replication. This work transforms PdpC from an orphan virulence factor into a tractable molecular switch at the heart of Francisella ’s intracellular lifestyle and a potential target for anti-tularemia therapeutics.
- Open Access
- 11 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e442-e447
Adding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice
We previously identified a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (parabolic response surface [PRS] regimen V) that dramatically shortens by approximately 85% the treatment duration needed to attain relapse-free cure of tuberculosis in mice compared with the standard regimen. Here, we investigated if intranasal administration of the PRS regimen V antibiotics bedaquiline and delamanid on top of the oral regimen would further accelerate tuberculosis cure in mice. We show that adding the intranasal to oral regimen further lowers lung burden of tubercle bacilli and significantly more rapidly achieves relapse-free cure. Hence, adding inhalational to oral therapy can potentially accelerate cure of tuberculosis.
- 11 June 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e442-e447
Open AccessAdding Intranasal to Oral Administration of an Ultra-Rapid Near-Universal Drug Regimen Accelerates Relapse-Free Cure of Tuberculosis in Mice
We previously identified a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (parabolic response surface [PRS] regimen V) that dramatically shortens by approximately 85% the treatment duration needed to attain relapse-free cure of tuberculosis in mice compared with the standard regimen. Here, we investigated if intranasal administration of the PRS regimen V antibiotics bedaquiline and delamanid on top of the oral regimen would further accelerate tuberculosis cure in mice. We show that adding the intranasal to oral regimen further lowers lung burden of tubercle bacilli and significantly more rapidly achieves relapse-free cure. Hence, adding inhalational to oral therapy can potentially accelerate cure of tuberculosis.
- Open Access
- 5 June 2025
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (12) , 1048-1053
Structure, identification, and characterization of the RibD-enolase complex in Francisella
- 5 June 2025
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (12) , 1048-1053
Open AccessStructure, identification, and characterization of the RibD-enolase complex in Francisella
- Open Access
- 5 January 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (2) , 155-168
Human alveolar lining fluid from the elderly promotes Mycobacterium tuberculosis intracellular growth and translocation into the cytosol of alveolar epithelial cells
- 5 January 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (2) , 155-168
Open AccessHuman alveolar lining fluid from the elderly promotes Mycobacterium tuberculosis intracellular growth and translocation into the cytosol of alveolar epithelial cells
- 10 March 2022
- Published by Taylor & Francis
- p. 25-76
Analysis of Post-Phagocytic Events: Membrane trafficking and the Mycobacterium tuberculosis phagosome
Mycobacterium tuberculosis subverts the normal membrane trafficking pathway of the host cell: it prevents the maturation and acidification of its phagosome, and thereby achieves a phagosome that is hospitable for its growth. The composition of the phagosome and the interactions between the phagosome and other host cell organelles have been studied by a variety of different techniques, including transmission electron microscopy, immunoelectron microscopy, immunofluorescence microscopy, and biochemical and immunological analysis of isolated phagosomes. In addition, the pH of the phagosome has been studied both by fluorescence and electron microscopy based techniques. Each of these methods for characterizing the properties and 26the membrane trafficking interactions of the M. tuberculosis phagosome has advantages and disadvantages, and each technique has the capacity to complement the other techniques in providing a more complete picture of the composition and membrane trafficking interactions of the M. tuberculosis phagosome.
- 10 March 2022
- Published by Taylor & Francis
- p. 25-76
Analysis of Post-Phagocytic Events: Membrane trafficking and the Mycobacterium tuberculosis phagosome
Mycobacterium tuberculosis subverts the normal membrane trafficking pathway of the host cell: it prevents the maturation and acidification of its phagosome, and thereby achieves a phagosome that is hospitable for its growth. The composition of the phagosome and the interactions between the phagosome and other host cell organelles have been studied by a variety of different techniques, including transmission electron microscopy, immunoelectron microscopy, immunofluorescence microscopy, and biochemical and immunological analysis of isolated phagosomes. In addition, the pH of the phagosome has been studied both by fluorescence and electron microscopy based techniques. Each of these methods for characterizing the properties and 26the membrane trafficking interactions of the M. tuberculosis phagosome has advantages and disadvantages, and each technique has the capacity to complement the other techniques in providing a more complete picture of the composition and membrane trafficking interactions of the M. tuberculosis phagosome.
- Open Access
- 18 September 2019
- Published by Wiley in Advanced Therapeutics
- Vol. 3 (4)
AI‐Enabled Parabolic Response Surface Approach Identifies Ultra Short‐Course Near‐Universal TB Drug Regimens
Tuberculosis (TB) is a major health problem that causes more deaths worldwide than any other single infectious disease. Current multidrug therapy for tuberculosis is exceedingly lengthy, leading to poor drug adherence, and consequently the emergence of drug resistance. Hence, much more rapid treatments are needed. Experimentally identifying the most synergistic drug combinations among available drugs is complicated by the astronomical number of possible drug‐dose combinations. This problem is dealt with by the use of an artificial‐intelligence‐enabled parabolic response surface platform in conjunction with an in vitro Mycobacterium tuberculosis–infected macrophage cell culture assay amenable to high‐throughput screening. This strategy allows rapid identification of the most effective drug‐dose combinations by testing only a small fraction of the total drug‐dose efficacy response surface. The same platform is then used to optimize the in vivo doses of each drug in the most potent regimens. Thus, regimens are identified that are dramatically more effective than the Standard Regimen in treating TB in a mouse model—a model broadly predictive of drug efficacy in humans. The most effective regimens reported herein shorten the duration of treatment required to achieve relapse‐free cure by 80% and are suitable for treating both drug‐sensitive and most drug‐resistant cases of tuberculosis.
- 18 September 2019
- Published by Wiley in Advanced Therapeutics
- Vol. 3 (4)
Open AccessAI‐Enabled Parabolic Response Surface Approach Identifies Ultra Short‐Course Near‐Universal TB Drug Regimens
Tuberculosis (TB) is a major health problem that causes more deaths worldwide than any other single infectious disease. Current multidrug therapy for tuberculosis is exceedingly lengthy, leading to poor drug adherence, and consequently the emergence of drug resistance. Hence, much more rapid treatments are needed. Experimentally identifying the most synergistic drug combinations among available drugs is complicated by the astronomical number of possible drug‐dose combinations. This problem is dealt with by the use of an artificial‐intelligence‐enabled parabolic response surface platform in conjunction with an in vitro Mycobacterium tuberculosis–infected macrophage cell culture assay amenable to high‐throughput screening. This strategy allows rapid identification of the most effective drug‐dose combinations by testing only a small fraction of the total drug‐dose efficacy response surface. The same platform is then used to optimize the in vivo doses of each drug in the most potent regimens. Thus, regimens are identified that are dramatically more effective than the Standard Regimen in treating TB in a mouse model—a model broadly predictive of drug efficacy in humans. The most effective regimens reported herein shorten the duration of treatment required to achieve relapse‐free cure by 80% and are suitable for treating both drug‐sensitive and most drug‐resistant cases of tuberculosis.
- 5 September 2019
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (9) , 10835-10844
Intracellular Photothermal Delivery for Suspension Cells Using Sharp Nanoscale Tips in Microwells
Efficient intracellular delivery of biomolecules into cells that grow in suspension is of great interest for biomedical research, such as for applications in cancer immunotherapy. Although tremendous effort has been expended, it remains challenging for existing transfer platforms to deliver materials efficiently into suspension cells. Here, we demonstrate a high-efficiency photothermal delivery approach for suspension cells using sharp nanoscale metal-coated tips positioned at the edge of microwells, which provide controllable membrane disruption for each cell in an array. Self-aligned microfabrication generates a uniform microwell array with three-dimensional nanoscale metallic sharp-tip structures. Suspension cells self-position by gravity within each microwell in direct contact with 8 sharp tips, where laser-induced cavitation bubbles generate transient pores in the cell membrane to facilitate intracellular delivery of extracellular cargo. A range of cargo sizes were tested on this platform using Ramos suspension B cells with an efficiency >84% for Calcein green (0.6 kDa) and >45% for FITC-dextran (2,000 kDa), with retained viability >96%, and a throughput >100,000 cells delivered per minute. The bacterial enzyme -lactamase (29 kDa) was delivered into Ramos B cells and retained its biological activity, whereas a green fluorescence protein (GFP) expression plasmid was delivered into Ramos B cells with a transfection efficiency of >58% and viability of >89% achieved.
- 5 September 2019
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (9) , 10835-10844
Intracellular Photothermal Delivery for Suspension Cells Using Sharp Nanoscale Tips in Microwells
Efficient intracellular delivery of biomolecules into cells that grow in suspension is of great interest for biomedical research, such as for applications in cancer immunotherapy. Although tremendous effort has been expended, it remains challenging for existing transfer platforms to deliver materials efficiently into suspension cells. Here, we demonstrate a high-efficiency photothermal delivery approach for suspension cells using sharp nanoscale metal-coated tips positioned at the edge of microwells, which provide controllable membrane disruption for each cell in an array. Self-aligned microfabrication generates a uniform microwell array with three-dimensional nanoscale metallic sharp-tip structures. Suspension cells self-position by gravity within each microwell in direct contact with 8 sharp tips, where laser-induced cavitation bubbles generate transient pores in the cell membrane to facilitate intracellular delivery of extracellular cargo. A range of cargo sizes were tested on this platform using Ramos suspension B cells with an efficiency >84% for Calcein green (0.6 kDa) and >45% for FITC-dextran (2,000 kDa), with retained viability >96%, and a throughput >100,000 cells delivered per minute. The bacterial enzyme -lactamase (29 kDa) was delivered into Ramos B cells and retained its biological activity, whereas a green fluorescence protein (GFP) expression plasmid was delivered into Ramos B cells with a transfection efficiency of >58% and viability of >89% achieved.
- Open Access
- 10 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0215607
Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs
Shorter, more effective treatments for tuberculosis (TB) are urgently needed. While many TB drugs are available, identification of the best regimens is challenging because of the large number of possible drug-dose combinations. We have found consistently that responses of cells or whole animals to drug-dose stimulations fit a parabolic response surface (PRS), allowing us to identify and optimize the best drug combinations by testing only a small fraction of the total search space. Previously, we used PRS methodology to identify three regimens (PRS Regimens I–III) that in murine models are much more effective than the standard regimen used to treat TB. However, PRS Regimens I and II are unsuitable for treating drug-resistant TB and PRS Regimen III includes an experimental drug. Here, we use PRS methodology to identify from an expanded pool of drugs new highly effective near-universal drug regimens comprising only approved drugs. We evaluated combinations of 15 different drugs in a human macrophage TB model and identified the most promising 4-drug combinations. We then tested 14 of these combinations in Mycobacterium tuberculosis-infected BALB/c mice and chose for PRS dose optimization and further study the two most potent regimens, designated PRS Regimens IV and V, consisting of clofazimine (CFZ), bedaquiline (BDQ), pyrazinamide (PZA), and either amoxicillin/clavulanate (AC) or delamanid (DLM), respectively. We then evaluated the efficacy in mice of optimized PRS Regimens IV and V, as well as a 3-drug regimen, PRS Regimen VI (CFZ, BDQ, and PZA), and compared their efficacy to PRS Regimen III (CFZ, BDQ, PZA, and SQ109), previously shown to reduce the time to achieve relapse-free cure in mice by 80% compared with the Standard Regimen (isoniazid, rifampicin, PZA, and ethambutol). Efficacy measurements included early bactericidal activity, time to lung sterilization, and time to relapse-free cure. PRS Regimens III–VI all rapidly sterilized the lungs and achieved relapse-free cure in 3 weeks (PRS Regimens III, V, and VI) or 5 weeks (PRS Regimen IV). In contrast, mice treated with the Standard Regimen still had high numbers of bacteria in their lungs after 6-weeks treatment and none achieved relapse-free cure in this time-period. We have identified three new regimens that rapidly sterilize the lungs of mice and dramatically shorten the time required to achieve relapse-free cure. All mouse drug doses in these regimens extrapolate to doses that are readily achievable in humans. Because PRS Regimens IV and V contain only one first line drug (PZA) and exclude fluoroquinolones and aminoglycosides, they should be effective against most TB cases that are multidrug resistant (MDR-TB) and many that are extensively drug-resistant (XDR-TB). Hence, these regimens have potential to shorten dramatically the time required for treatment of both drug-sensitive and drug-resistant TB. If clinical trials confirm that these regimens dramatically shorten the time required to achieve relapse-free cure in humans, then this radically shortened treatment has the potential to improve treatment compliance, decrease the emergence of drug resistance, and decrease the healthcare burden of treating both drug-sensitive and drug-resistant TB.
- 10 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0215607
Open AccessArtificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs
Shorter, more effective treatments for tuberculosis (TB) are urgently needed. While many TB drugs are available, identification of the best regimens is challenging because of the large number of possible drug-dose combinations. We have found consistently that responses of cells or whole animals to drug-dose stimulations fit a parabolic response surface (PRS), allowing us to identify and optimize the best drug combinations by testing only a small fraction of the total search space. Previously, we used PRS methodology to identify three regimens (PRS Regimens I–III) that in murine models are much more effective than the standard regimen used to treat TB. However, PRS Regimens I and II are unsuitable for treating drug-resistant TB and PRS Regimen III includes an experimental drug. Here, we use PRS methodology to identify from an expanded pool of drugs new highly effective near-universal drug regimens comprising only approved drugs. We evaluated combinations of 15 different drugs in a human macrophage TB model and identified the most promising 4-drug combinations. We then tested 14 of these combinations in Mycobacterium tuberculosis-infected BALB/c mice and chose for PRS dose optimization and further study the two most potent regimens, designated PRS Regimens IV and V, consisting of clofazimine (CFZ), bedaquiline (BDQ), pyrazinamide (PZA), and either amoxicillin/clavulanate (AC) or delamanid (DLM), respectively. We then evaluated the efficacy in mice of optimized PRS Regimens IV and V, as well as a 3-drug regimen, PRS Regimen VI (CFZ, BDQ, and PZA), and compared their efficacy to PRS Regimen III (CFZ, BDQ, PZA, and SQ109), previously shown to reduce the time to achieve relapse-free cure in mice by 80% compared with the Standard Regimen (isoniazid, rifampicin, PZA, and ethambutol). Efficacy measurements included early bactericidal activity, time to lung sterilization, and time to relapse-free cure. PRS Regimens III–VI all rapidly sterilized the lungs and achieved relapse-free cure in 3 weeks (PRS Regimens III, V, and VI) or 5 weeks (PRS Regimen IV). In contrast, mice treated with the Standard Regimen still had high numbers of bacteria in their lungs after 6-weeks treatment and none achieved relapse-free cure in this time-period. We have identified three new regimens that rapidly sterilize the lungs of mice and dramatically shorten the time required to achieve relapse-free cure. All mouse drug doses in these regimens extrapolate to doses that are readily achievable in humans. Because PRS Regimens IV and V contain only one first line drug (PZA) and exclude fluoroquinolones and aminoglycosides, they should be effective against most TB cases that are multidrug resistant (MDR-TB) and many that are extensively drug-resistant (XDR-TB). Hence, these regimens have potential to shorten dramatically the time required for treatment of both drug-sensitive and drug-resistant TB. If clinical trials confirm that these regimens dramatically shorten the time required to achieve relapse-free cure in humans, then this radically shortened treatment has the potential to improve treatment compliance, decrease the emergence of drug resistance, and decrease the healthcare burden of treating both drug-sensitive and drug-resistant TB.